The US Bipartisan Bio-Detection 2011 Report Card Status Evaluation
(Source: The US Bipartisan WMD Terrorism Research Center, October 2011 Bio Response Report Card)
Events of the recent decade confirm that the threats of bio-terrorism and infectious disease outbreaks are real. Attacks such as the 2001 Anthrax scare, the 2004 Ricin letters, the 2003 SARS and 2009 H1N1 outbreaks have driven governments to increase their bio-surveillance budgets. Public healthcare and HLS agencies’ urgent need to establish an early and reliable bio-surveillance detection infrastructure will drive the market onto a much higher trajectory than ever before. We forecast that the cumulative 2012-2016 market (including: systems sale, consumables, upgrades and service) will reach $22.8 billion.
The recent year that saw the seventh review round of the Biological and Toxic Weapons Convention, demonstrated that demand for biosecurity remains high. As developed countries continue to refine their organizational and technological approach to potential bio-terror and disease outbreak threats, many key emerging markets are also ramping up programs to acquire solutions that provide early outbreak-attack detection. These will require the shortening of bio-attack alarm response time and the proliferation of 3rd generation cost-effective bio-detection technologies and reagent-less detection assays.
In contrast to the US colossal spending of $67 billion on biodefense programs during the 2001-2011 period, the US bipartisan WMD Terror Response Center report card (September 2011) graded the world’s leading “US bio-detection and attribution programs” as the Achilles heel of the US BioWatch program. It received a score ranging from “meets minimal expectations” to a catastrophic “fails to meet expectations” (see table above). It stated that “Although naturally occurring disease remains a serious threat, a thinking enemy armed with these same pathogens, or with multi–drug resistant or synthetically engineered pathogens could produce catastrophic consequences“.
Over the next five years, we forecast that, led by the US, Germany, France, China, Japan and India, the global bio-detection market (including systems sale, service, upgrades and consumables) will reach $5.6 billion by 2016.
HSRC analyses, forecasts and projected business opportunities are presented in the recent report: Bio-Terror & Infectious Disease Outbreak Detection: Technologies and Global Markets – 2012 Edition. With 355 pages, 95 tables and 146 figures, this report represents a landmark bio-detection technologies and market picture.
Developed using HSRC’s tested market research methodology, the report delves into:
- 76 bio-detection sub-markets
- 34 leading bio-detection technology vendors
- Regional markets: e.g., USA, UK, Germany, France, Italy, Spain, China, Taiwan, Japan, India, Middle East
- Global bio-detection market segmented by systems sales and upgrade, service & consumables segments
- Global market by first, second and third generation technology
- Global market by indoor, outdoor, hand-held and mobile labs segments
- Current and pipeline technologies: e.g., advanced collectors-concentrators, reagent-less triggers, DNA-based diagnostics, antigen/anti-body methods, signal analysis algorithms
- Business opportunities: e.g., emerging threats, human and animal sentinel surveillance, reagent-less detection assays, bio-detection IC3 systems
- Competitive and SWOT analyses
- 45 key bio detection products pricing data
- And much more…
Phi Beta Iota: The US Government approach to health is criminally insane — it forces people into a profit driven system that is out of control and not accountable for results, while nurturing two criminal drug empires: illegal drugs and legal drugs. The time has come for communities to self-fund health and nullify federal and state mandates that do not make sense.